Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182246 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL5943739 | 0.91 | MEN1 (0.52) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL6182800 | 0.91 | MEN1 (0.52) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL2543712 | 0.87 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL792692 | 0.87 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL3321644 | 0.87 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL550224 | 0.87 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2APOLBMAPT | |
| SCHEMBL2549257 | 0.86 | MEN1 (0.47) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL31555712 | 0.86 | MEN1 (0.47) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL18391124 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1478437-A1 | ACC INHIBITORS | Pfizer Products Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003072197-A1 | ACC INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | ALDH1A1 654/4885MEN1 3712/4885KMT2A 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.